Mylan N.V. announced that its Board of Directors has unanimously rejected the unsolicited expression of interest from Teva Pharmaceutical Industries Ltd. to acquire Mylan, which was announced on April 21, 2015 (see our news story).
According to a press release, after a comprehensive review conducted in consultation with its financial and legal advisors, the Mylan Board concluded the approach did not meet any of the key criteria that would cause the company to depart from the its successful and longstanding standalone strategy, and consider engaging in discussions to sell the Company.
Mylan's executive chairman Robert J. Coury said, "Our Board has a very important fiduciary obligation to protect the best interests of the Company's shareholders and other stakeholders, and has always been open to considering all paths forward in that regard, and this situation is no different. However, that does not mean we will entertain offers that grossly undervalue the company, and leave our shareholders and other stakeholders exposed to serious risk.
"After thorough consideration, Mylan's Board unanimously determined that Teva's proposal grossly undervalues Mylan, and would require Mylan's shareholders to accept what we believe are low-quality Teva shares in exchange for their high-quality Mylan shares in a transaction that lacks industrial logic and carries significant global antitrust risk. In addition, we also believe that the proposal does not address the serious challenges of integrating two fundamentally different and conflicting cultures under a Teva Board and leadership team with a poor record of delivering sustainable shareholder value. We believe that these challenges would make it very difficult to generate value from this combination for Mylan shareholders.
"Furthermore, the proposal contains nothing meaningful indicating why a combination with Teva would be in the best interest of Mylan's employees, patients, customers, communities and other stakeholders."
Read the full release